Current Medical Treatment of Glioblastoma

Venur, Vyshak Alva; Peereboom, David M.; Ahluwalia, Manmeet

doi:10.1007/978-3-319-12048-5_7

Cited by 72 publications

(64 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drugs considered most active are the temozolomide and fotemustine [12]. Antiangiogenic and particularly the bevacizumab appear promising but not used in first line therapy.…”

Section: Discussionmentioning

confidence: 99%

Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy

Pastore¹,

Fioranelli²,

Roccia³

2017

J Integr Oncol

View full text Add to dashboard Cite

Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surgically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic drug, RF capacitive hyperthermia and herbal medicine, earns an acceptable quality of life and survival prolongation of six months.

show abstract

“…Drugs considered most active are the temozolomide and fotemustine [12]. Antiangiogenic and particularly the bevacizumab appear promising but not used in first line therapy.…”

Section: Discussionmentioning

confidence: 99%

Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy

Pastore¹,

Fioranelli²,

Roccia³

2017

J Integr Oncol

View full text Add to dashboard Cite

show abstract

“…The processes of proliferation and invasion of malignant glioma cells are presumed to be mutually exclusive and the term Bgo or grow^has commonly been used to describe this behavior [22,58,64]. In previous investigations of this phenotypic axis, signaling molecules such as miRNAs and proteins have been characteristically revealed as monotonic regulators of growth or invasion [1,12,22,65].…”

Section: Discussionmentioning

confidence: 99%

Density-Dependent Regulation of Glioma Cell Proliferation and Invasion Mediated by miR-9

Katakowski

Charteris

Chopp

et al. 2016

Cancer Microenvironment

View full text Add to dashboard Cite

The phenotypic axis of invasion and proliferation in malignant glioma cells is a well-documented phenomenon. Invasive glioma cells exhibit a decreased proliferation rate and a resistance to apoptosis, and invasive tumor cells dispersed in brain subsequently revert to proliferation and contribute to secondary tumor formation. One miRNA can affect dozens of mRNAs, and some miRNAs are potent oncogenes. Multiple miRNAs are implicated in glioma malignancy, and several of which have been identified to regulate tumor cell motility and division. Using rat 9 L gliosarcoma and human U87 glioblastoma cell lines, we investigated miRNAs associated with the switch between glioma cell invasion and proliferation. Using micro-dissection of 9 L glioma tumor xenografts in rat brain, we identified disparate expression of miR-9 between cells within the periphery of the primary tumor, and those comprising tumor islets within the invasive zone. Modifying miR-9 expression in in vitro assays, we report that miR-9 controls the axis of glioma cell invasion/proliferation, and that its contribution to invasion or proliferation is biphasic and dependent upon local tumor cell density. In addition, immunohistochemistry revealed elevated hypoxia inducible factor 1 alpha (HIF-1α) in the invasive zone as compared to the primary tumor periphery. We also found that hypoxia promotes miR-9 expression in glioma cells. Based upon these findings, we propose a hypothesis for the contribution of miR-9 to the dynamics glioma invasion and satellite tumor formation in brain adjacent to tumor.

show abstract

“…[4] In addition to classic treatments, there are other adjuvant therapies such as glucocorticoids to reduce the peritumoral edema, antiangiogenic agents like bevacicumab (Avastin) which prolongs the progression-free survival; [5] However, a randomized trial showed that patients who consumed bevacizumab suffered from hypertension, thromboembolic events, intestinal perforation, and neutropenia. [6] Progressive brain volume loss have been observed with classic radio chemotherapy treatment resulting to neuropsychological changes in patients with glioblastoma.…”

Section: Current Cancer Therapy For Glioblastomamentioning

confidence: 99%